Amalgamated Bank Sells 774 Shares of Waters Co. (NYSE:WAT)

Amalgamated Bank decreased its stake in Waters Co. (NYSE:WAT) by 5.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,621 shares of the medical instruments supplier’s stock after selling 774 shares during the period. Amalgamated Bank’s holdings in Waters were worth $4,814,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of WAT. Exchange Traded Concepts LLC acquired a new stake in Waters in the fourth quarter valued at $35,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Waters in the 3rd quarter valued at about $33,000. Wetzel Investment Advisors Inc. bought a new position in Waters during the fourth quarter worth about $39,000. Turtle Creek Wealth Advisors LLC acquired a new position in Waters during the fourth quarter worth approximately $41,000. Finally, VisionPoint Advisory Group LLC raised its stake in Waters by 300.0% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 108 shares during the period. Institutional investors and hedge funds own 94.01% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Stifel Nicolaus boosted their target price on Waters from $290.00 to $330.00 and gave the stock a “hold” rating in a report on Wednesday, February 7th. Evercore ISI upped their price objective on shares of Waters from $320.00 to $340.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Finally, Barclays raised their target price on shares of Waters from $275.00 to $300.00 and gave the stock an “underweight” rating in a research note on Monday, February 12th. One research analyst has rated the stock with a sell rating and eight have given a hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $298.67.

Waters Price Performance

NYSE:WAT opened at $326.06 on Wednesday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 1.57 and a current ratio of 2.22. The firm has a market cap of $19.34 billion, a price-to-earnings ratio of 30.05, a P/E/G ratio of 6.39 and a beta of 0.98. Waters Co. has a 52 week low of $231.90 and a 52 week high of $363.80. The firm’s 50-day simple moving average is $333.23 and its 200 day simple moving average is $310.76.

Waters (NYSE:WAT) last announced its earnings results on Tuesday, February 6th. The medical instruments supplier reported $3.62 EPS for the quarter, topping the consensus estimate of $3.56 by $0.06. The company had revenue of $819.50 million for the quarter, compared to analysts’ expectations of $815.50 million. Waters had a net margin of 21.72% and a return on equity of 81.30%. The business’s revenue for the quarter was down 4.5% on a year-over-year basis. During the same period last year, the firm earned $3.84 earnings per share. As a group, sell-side analysts predict that Waters Co. will post 11.89 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Linda Baddour sold 500 shares of the business’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $355.54, for a total value of $177,770.00. Following the completion of the transaction, the director now owns 2,250 shares of the company’s stock, valued at $799,965. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.82% of the company’s stock.

Waters Company Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.